Infant neutropenia associated with breastfeeding during maternal antiretroviral treatment for prevention of mother-to-child transmission of hiv
View/ Open
Date
2014Author
Njuguna, Irene
Marie, Reilly
Walter, Jaoko
Gichuhi, Christine
Gwen, Ambler
Elizabeth, Maleche-Obimbo
Barbara, Lohman-Payne
Hanke, Tomáš
John-Stewart, Grace
Language
enMetadata
Show full item recordAbstract
Maternal antiretroviral treatment (ART) is recommended for prevention of mother-to-child HIV-1 transmission (PMTCT), including in women with high CD4+ cell counts. Within a pediatric HIV-1 vaccine trial PedVacc 002, we assessed hematologic profiles of infants born to mothers receiving ART. All mothers had CD4+ cell counts of >350 mm-3; 93% received zidovudine-containing ART; infants received nevirapine up to 6 weeks and cotrimoxazole after 6 weeks. Among 84 infants at 19 weeks, 58% had hematologic toxicity; 44% had neutropenia and 23% had anemia. Breastfeeding was associated with 3.8-fold higher risk of neutropenia (RR 3.8, 95% CI 1.03-14.1, p = 0.008). Hematologic monitoring and PMTCT regimen selection are important for optimizing infant outcomes
Publisher
University of Nairobi
Collections
- Faculty of Health Sciences (FHS) [10385]